Insulet Revenue 2012-2025 | PODD
Insulet annual/quarterly revenue history and growth rate from 2012 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Insulet revenue for the quarter ending September 30, 2025 was $0.706B, a 29.86% increase year-over-year.
- Insulet revenue for the twelve months ending September 30, 2025 was $2.522B, a 27.12% increase year-over-year.
- Insulet annual revenue for 2024 was $2.072B, a 22.07% increase from 2023.
- Insulet annual revenue for 2023 was $1.697B, a 30.02% increase from 2022.
- Insulet annual revenue for 2022 was $1.305B, a 18.79% increase from 2021.
|
Insulet Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $2,072 |
| 2023 | $1,697 |
| 2022 | $1,305 |
| 2021 | $1,099 |
| 2020 | $904 |
| 2019 | $738 |
| 2018 | $564 |
| 2017 | $464 |
| 2016 | $367 |
| 2015 | $264 |
| 2014 | $231 |
| 2013 | $247 |
| 2012 | $211 |
| 2011 | $152 |
|
Insulet Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-09-30 | $706 |
| 2025-06-30 | $649 |
| 2025-03-31 | $569 |
| 2024-12-31 | $598 |
| 2024-09-30 | $544 |
| 2024-06-30 | $489 |
| 2024-03-31 | $442 |
| 2023-12-31 | $510 |
| 2023-09-30 | $433 |
| 2023-06-30 | $397 |
| 2023-03-31 | $358 |
| 2022-12-31 | $370 |
| 2022-09-30 | $341 |
| 2022-06-30 | $299 |
| 2022-03-31 | $295 |
| 2021-12-31 | $308 |
| 2021-09-30 | $276 |
| 2021-06-30 | $263 |
| 2021-03-31 | $252 |
| 2020-12-31 | $246 |
| 2020-09-30 | $234 |
| 2020-06-30 | $226 |
| 2020-03-31 | $198 |
| 2019-12-31 | $209 |
| 2019-09-30 | $192 |
| 2019-06-30 | $177 |
| 2019-03-31 | $160 |
| 2018-12-31 | $165 |
| 2018-09-30 | $151 |
| 2018-06-30 | $124 |
| 2018-03-31 | $124 |
| 2017-12-31 | $131 |
| 2017-09-30 | $122 |
| 2017-06-30 | $110 |
| 2017-03-31 | $102 |
| 2016-12-31 | $104 |
| 2016-09-30 | $95 |
| 2016-06-30 | $87 |
| 2016-03-31 | $81 |
| 2015-12-31 | $84 |
| 2015-09-30 | $71 |
| 2015-06-30 | $61 |
| 2015-03-31 | $48 |
| 2014-12-31 | $15 |
| 2014-09-30 | $75 |
| 2014-06-30 | $72 |
| 2014-03-31 | $69 |
| 2013-12-31 | $69 |
| 2013-09-30 | $61 |
| 2013-06-30 | $60 |
| 2013-03-31 | $57 |
| 2012-12-31 | $58 |
| 2012-09-30 | $55 |
| 2012-06-30 | $51 |
| 2012-03-31 | $48 |
| 2011-12-31 | $47 |
| 2011-09-30 | $45 |
| 2011-06-30 | $32 |
| 2011-03-31 | $28 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $19.568B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $216.142B | 24.91 |
| EssilorLuxottica (ESLOY) | France | $149.893B | 0.00 |
| Boston Scientific (BSX) | United States | $139.557B | 31.91 |
| Stryker (SYK) | United States | $136.074B | 27.02 |
| Medtronic (MDT) | Ireland | $123.612B | 17.13 |
| Medline (MDLN) | United States | $56.293B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.245B | 0.00 |
| Agilent Technologies (A) | United States | $41.482B | 26.22 |
| GE HealthCare Technologies (GEHC) | United States | $38.615B | 18.47 |
| ResMed (RMD) | United States | $37.167B | 25.72 |
| Koninklijke Philips (PHG) | Netherlands | $28.531B | 18.64 |
| Terumo (TRUMY) | Japan | $21.128B | 23.78 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.507B | 10.92 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.553B | 0.00 |
| Baxter (BAX) | United States | $10.101B | 8.15 |
| Sunny Optical Technology (SNPTF) | China | $9.589B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.690B | 31.25 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| BillionToOne (BLLN) | United States | $4.433B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.366B | 13.30 |
| Envista Holdings (NVST) | United States | $3.820B | 21.92 |
| Haemonetics (HAE) | United States | $3.690B | 16.42 |
| ICU Medical (ICUI) | United States | $3.661B | 23.24 |
| Prestige Consumer Healthcare (PBH) | United States | $3.111B | 14.19 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.262B | 14.54 |
| Perrigo (PRGO) | Ireland | $2.073B | 5.19 |
| Neogen (NEOG) | United States | $1.999B | 43.76 |
| LeMaitre Vascular (LMAT) | United States | $1.891B | 38.06 |
| AtriCure (ATRC) | United States | $1.810B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.784B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.742B | 76.36 |
| Phibro Animal Health (PAHC) | United States | $1.640B | 16.38 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.515B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.437B | 20.80 |
| Kestra Medical Technologies (KMTS) | United States | $1.286B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.151B | 341.43 |
| Capricor Therapeutics (CAPR) | United States | $1.133B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.054B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.028B | 0.00 |
| Omeros (OMER) | United States | $0.895B | 0.00 |
| InMode (INMD) | Israel | $0.887B | 10.02 |
| Valneva SE (VALN) | France | $0.864B | 0.00 |
| CeriBell (CBLL) | United States | $0.845B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.564B | 15.30 |
| Cerus (CERS) | United States | $0.484B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.476B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.472B | 0.00 |
| Brainsway (BWAY) | Israel | $0.467B | 79.45 |
| Canopy Growth (CGC) | Canada | $0.461B | 0.00 |
| SNDL (SNDL) | Canada | $0.434B | 0.00 |
| Evolus (EOLS) | United States | $0.371B | 0.00 |
| Quanterix (QTRX) | United States | $0.334B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.295B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.276B | 21.97 |
| Sanuwave Health (SNWV) | United States | $0.245B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.240B | 141.33 |
| TerrAscend (TSNDF) | Canada | $0.236B | 0.00 |
| High Tide (HITI) | Canada | $0.235B | 0.00 |
| Organigram Global (OGI) | Canada | $0.228B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Sanara MedTech (SMTI) | United States | $0.211B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.197B | 0.00 |
| Accendra Health (ACH) | United States | $0.194B | 1.95 |
| Utah Medical Products (UTMD) | United States | $0.188B | 16.54 |
| OraSure Technologies (OSUR) | United States | $0.187B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.158B | 0.00 |
| Apyx Medical (APYX) | United States | $0.148B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.135B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.117B | 0.00 |
| Exagen (XGN) | United States | $0.117B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.76 |
| Biote (BTMD) | United States | $0.111B | 4.86 |
| MacroGenics (MGNX) | United States | $0.111B | 0.00 |
| Sharps Technology (STSS) | United States | $0.061B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 25.58 |
| Nephros (NEPH) | United States | $0.047B | 34.00 |
| Cytosorbents (CTSO) | United States | $0.046B | 0.00 |
| Veru (VERU) | United States | $0.039B | 0.00 |
| Jin Medical (ZJYL) | China | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.029B | 14.57 |
| Cellectar Biosciences (CLRB) | United States | $0.017B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Bonk (BNKK) | United States | $0.014B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |